University of Navarra
If you are the contact person for this centre and you wish to make any changes, please contact us.
PhD in Pharmacy, Professor of Human Physiology at the University of Navarra, member of the CIBER Physiopathology of Obesity, Carlos III Health Institute and IDISNA (Navarra)
Researcher in the Gene Therapy and Regulation of Gene Expression Programme and Director of Innovation and Transfer at Cima University of Navarra
Professor of Immunology at the University of Navarra, CIMA researcher and co-director of the Department of Immunology and Immunotherapy at the Clínica Universidad de Navarra.
Senior Researcher of the Gene Therapy in Neurodegenerative Diseases Programme at the Centre for Applied Medical Research (CIMA), University of Navarra
Co-coordinator of the working group on Nutrition of the Spanish Society of Epidemiology (SEE), Professor of Preventive Medicine and Public Health at the University of Navarra, and member of CIBERobn
Professor of Preventive Medicine and Public Health at the University of Navarra and Adjunct Professor in the Department of Nutrition at the Harvard T.H. Chan School of Public Health (United States)
Professor and Head of the Preventive Medicine and Public Health Department
Researcher of the Gene Therapy and Regulation of Gene Expression Programme at Cima (Centre for Applied Medical Research) University of Navarra
Researcher at the Laboratory of Experimental Ophthalmology, Faculty of Medicine, University of Navarra
The use of the antidepressants escitalopram, paroxetine, and duloxetine is associated with greater weight gain than the use of sertraline, according to the results of an analysis comparing data from more than 183,000 adults treated with one of eight types of antidepressants. Among these, bupropion is associated with the least weight gain, concludes the study, which is published in Annals of Internal Medicine.
People who take multivitamins daily do not have a lower risk of mortality than people who do not use these products, according to a meta-analysis published in JAMA Network Open. The study pooled data from more than 390,000 people, followed for about 20 years in three different cohorts in the United States.
CAR-T cell therapies may, in some cases, produce tumours secondary to treatment. A few months ago, the US Food and Drug Administration (FDA) said it was assessing this risk. Now, a study conducted at Stanford University Medical Center (USA) has tracked 724 patients who received this type of treatment since 2016. Of these, 14 developed another blood tumour, but only one was a T-cell lymphoma that could be a direct consequence of the therapy. Further analysis ruled out this link. The results are published in the journal NEJM.
People who eat more ultra-processed foods have a "slightly higher" mortality rate, according to an analysis published in The BMJ. The study analysed data from more than 110,000 people followed up for over 30 years in the United States. The correlation between ultra-processed food intake and all-cause mortality was strongest for the meat, poultry and seafood group.
A monoclonal antibody called prasinezumab reduces the worsening of motor symptoms in people with Parkinson's disease who have rapidly progressive disease, according to an analysis of a phase 2 clinical trial published in Nature Medicine. These findings suggest that clinical efficacy of prasinezumab, which works by binding to alpha-synuclein protein aggregates, is seen after one year of treatment in such patients. According to the authors, more research is needed to determine whether the antibody can be effective in people with slower disease progression after longer periods of treatment.
A phase 2 clinical trial in France has examined whether taking an oral anti-diabetic drug called lixisenatide - a GLP1 receptor analogue, similar to those also used for weight loss - also has an effect on the progression of Parkinson's disease. The results indicate that there is a modest but significant decrease in the progression of motor symptoms of the disease, although side effects were also observed. The results are published in the journal NEJM.
Ingesting small amounts of apple cider vinegar daily for three months helps control weight in overweight or obese people, according to a clinical trial involving 120 young Lebanese people. The results, published in the journal BMJ Nutrition, Prevention & Health, show that consumption of this substance - which has become fashionable among some celebrities - was associated with decreases in weight, body mass index and blood levels of glucose, triglycerides and cholesterol. The authors suggest that this substance could serve as a complementary treatment for obesity.
Eating more ultra-processed foods is linked to a higher risk of health problems, according to an umbrella review of 45 previous meta-analyses, involving almost 10 million people in total. The research, published in The BMJ, finds direct associations between exposure to ultra-processed foods and 32 health parameters. The strongest evidence links this exposure to cardiometabolic health problems, mental disorders and overall mortality.
A multidisciplinary study involving several Spanish research groups has preclinically tested a new type of immunotherapy for multiple myeloma. Instead of modifying T cells to attack the tumour directly, as CAR-T cells do, they have managed to make them secrete bispecific antibodies, which bind to the tumour on one side and to other T cells on the other, attracting them to the tumour. According to the authors, this cell therapy was more effective than traditional CAR-Ts and could generate less resistance. The results are published in the journal Science Translational Medicine.
The US Food and Drug Administration (FDA) has issued a statement reporting that it has received reports of T-cell tumours in patients who received various CAR-T cell treatments. As quoted in the statement, "although the overall benefits of these products continue to outweigh their potential risks for their approved uses, FDA is investigating the identified risk of T cell malignancy with serious outcomes, including hospitalization and death, and is evaluating the need for regulatory action".